Article Text

Download PDFPDF
Pharmacological interventions
Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t)
  1. Marco Solmi1,2,
  2. Christoph U Correll3,4,5,6
  1. 1 Neuroscience Department, University of Padua, Padua, Italy
  2. 2 Neuroscience Centre, University of Padua, Padua, Italy
  3. 3 Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, New York, USA
  4. 4 Hofstra Northwell School of Medicine, Hempstead, New York, USA
  5. 5 The Feinstein Institute for Medical Research, Manhasset, New York, USA
  6. 6 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
  1. Correspondence to Dr Marco Solmi, Neuroscience Department, University of Padua, Padova 35122, Italy; marco.solmi83{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Deakin B, Suckling J, Barnes TRE, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry 2018;5:885–94.

What is already known on this topic

Minocycline has been proposed as treatment for negative symptoms in schizophrenia due to its neuroprotective and anti-inflammatory properties. In two recent meta-analyses1 2 of randomised controlled trials (RCTs), minocycline outperformed placebo regarding total, general and negative symptoms. However, negative results of a large RCT (BeneMin)3 have been recently published.

Methods of the study

Population: Patients with first-episode schizophreniform disorder, schizoaffective disorder or schizophrenia within 5 years of illness onset, mild to moderate severity and positive symptoms (Positive and Negative Symptoms Scale …

View Full Text


  • Contributors Both authors had the idea, wrote and approved the submitted commentary.

  • Competing interests CUC has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ROVI, Sunovion, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Janssen and Takeda. He is a shareholder of LB Pharma.

  • Provenance and peer review Commissioned; internally peer reviewed.